DDM-026 - Fabrication and characterization of a novel drug delivery platform for metastatic triple negative breast cancer

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: DDM-026
• By: ALDHAFEERI, Bashayr (School of Pharmacy, The University Of Sydney, Australia)
• Co-author(s): Mrs Bashayr Aldhafeeri (School of Pharmacy, The University Of Sydney, Sydney, Australia)
  Mr. Elemr Austria (School of Biomedical Engineering, University of Sydney, Sydney, Australia)
  Dr. Lufeng Zheng (China Pharmaceutical University, Nanjing, China)
  Dr. Behnam Akhavn (School of Biomedical Engineering, University of Sydney, Sydney, Australia / University of Sydney Nano Institute, The University of Sydney, Sydney , Australia )
  Dr. Pegah Varamini (School of Pharmacy, The University Of Sydney, Sydney, Australia / University of Sydney Nano Institute, The University of Sydney, Sydney , Australia )
  
• Abstract:

  Introduction: Triple-negative breast cancer (TNBC) is an aggressive form of cancer, and there are yearly around 2500 new cases of TNBC in Australia. TNBC is not amenable to anti-hormone therapy or anti-HER2 targeted therapy, due to the lack expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login